The Influenza Centre"> pub2010
PUBLICATIONS 2010 - 2014


• Koch AM, Nilsen RM, Dalheim A, Cox RJ, Harthug S. Monitoring infection prevalence in a major hospital; an important aspect of infection prevention and control programs. Journal of Infection and Public Healt 2014, J Infect Public Health. 2014. pii: S1876-0341(14)00182-8.

• Leonardi-Bee J, Venkatesan S, Muthuri SG, Nguyen-Van-Tam JS, Myles PR; PRIDE research consortium. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med. 2014 Jul;2(7):e10-2. doi: 10.1016/S2213-2600(14)70137-7.

• Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ Krammer F. Induction of broadly-reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Journal of Virology 2014 Nov;88(22):13260-8.

• Mart GP, Mohn KG, Cox RJ, Brokstad KA. The influence of tonsillectomy on total serum antibody levels. Scand J Immunol. 2014 Nov;80(5):377-9.

• Skrede S, Steinsland H, Sommerfelt H, Aase A, Brandtzaeg P, Langeland N, Cox RJ, Sævik M, Wallevik M, Skutlaberg DH, Tellevik MG, Sack DA, Nataro JP, Guttormsen AB. Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward. BMC Infectious Diseases 2014; Sep 4;14:482.

• Jul-Larsen Å, Cox RJ. Book Chapter Influenza Vaccines. Editor Dr Viroj Wiwanitkit ebook Influenza Management. 2014 in press.

• Greve-Isdahl Mohn K, Cox RJ. Vaksinasjon mot influensa? Best Practice 2014.

• Mair-Jenkins J, Saavedra-Campos M, Baillie K, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD; Convalescent Plasma Study Group, Nguyen-Van-Tam JS, Beck CR. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2014 Jul 16. pii: jiu396.

• Krammer F, Jul-Larsen Å, Margine I, Hirsh A, Sjursen H, Zambon M, Cox RJ. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clinical and Vaccine Immunology 2014 Jun 18. pii: CVI.00272-14. [Epub ahead of print]

• Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, Leon de Waal L, Veldhuis Kroeze EJB, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, Osterhaus ADME, Knight A, Oxford JS, Lapini G, Cox RJ, Lambkin-William R. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against Highly Pathogenic Influenza intranasal and intratracheal challenge. PLOSone 2014;9(5):e93761.

• Pedersen G, Hoschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ. Serum IgG titres, but not avidity, correlates with neutralising antibody response after H5N1 vaccination. Vaccine 2014, ul 31;32(35):4550-7.

• Pedersen G, Sjursen H, Nøstbakken JK, Jul-Larsen Å, Cox RJ. Matrix MTM adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man. Human Vaccines & Immunotherapeutics 2014, 2014;10(8):2408-16.

• Muthuri S, Venkatesan S, Myles P, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in hospitalized A(H1N1)pdm09 influenza patients. Lancet Respiratory Medicine 2014; 2 (5):395-404

• Krammer F, Albrecht RA, Tan G, Hai R, Margine I, Schmolke M, Runstadler J, Wilson P, Cox RJ, Treanor JJ, García-Sastre A, Palese P. Divergent H7 immunogens offer protection from H7N9 challenge. Journal of Virology 2014;88(8):3976-85

• Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients; an explorative study. Multiple Sclerosis Journal 2014 20: 1074-80.

• Greve‐Isdahl Mohn K, Lærum BN, Skrede S, Cox RJ, Dyrhol‐Riise AM, Simonsen HE, Langeland N, Aβmus J, Akselsen P-E, Sjursen H, Smith I. Reduced hospital stay in influenza patients after mass vaccination during the 2009 influenza pandemic in Norway. Vaccines and Vaccination 2013, 4:197. doi: 10.4172/2157-7560.1000197. http://omicsonline.org/reduced-hospital-stay-in-influenza-patients-after-mass-vaccination-during-the-2009-influenza-pandemic-in-norway-2157-7560-4-197.php?aid=18065

• Krammer F, Cox RJ. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Review of Vaccines 2013 Dec;12(12):1369-72.

• Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen A, Guzmán CA, Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinchcliffe M, Cox RJ. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses. 2013 Nov;7(6):1181-93.

• Cox RJ. Correlates of protection to influenza; where do we go from here? Human Vaccines & Immunotherapeutics 2013 Jan 4;9(2).

• Bredholt G, Pedersen GK, Pathirana RD, Akselsen PE, Cox RJ. Pandemic vaccination of healthcare workers: Improved immune responses in low responders following revaccination. Letter The Journal of Infectious Diseases 2013;207(7):1186-8.

• Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJ. A(H1N1)pdm09 vaccination of healthcare workers: Improved immune responses in low responders following revaccination. The Journal of Infectious Diseases 2012;206(11):1660-9.

• Pedersen G, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana R, Goudsmit J, Cox RJ .Th1 Cells Elicited by H5N1 Vaccination Predict Seroprotection. Journal of Infectious Diseases 2012;206(2):158-66.

• Jul-Larsen Å, Madhun AS, Brokstad KA, Montomoli E, Yusibov V, Cox RJ. The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Human Vaccines & Immunotherapeutics 2012 1;8(5).

• Pedersen GK, Cox RJ. The Mucosal Vaccine Quandary: Intranasal Versus Sublingual Immunisation Against Influenza. Human Vaccines and Immunotherapeutics 2012 1;8(5).

• Svindland SC, Jul-Larsen A, Pathirana R, Andersen S, Madhun A, Montomoli E, Gill I, Cox RJ. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses. 2012;6(2):90-100.

• Simonsen KA, Hunskaar S, Wensaas KA, Rortveit S, Cox R, Njolstad G, et al. Influenza-like illness in general practice in Norway: clinical course and attitudes towards vaccination and preventive measures during the 2009 pandemic. Fam Pract. 2012;29(2):139-46.

• Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzman CA, et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One. 2011;6(11):e26973.

• Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses. 2011 Nov;5(6):426-37.

• Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol. 2011 Aug;74(2):210-8.

• Madhun AS, Haaheim LR, Nostbakken JK, Ebensen T, Chichester J, Yusibov V, et al. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine. 2011 Jul 12;29(31):4973-82.

• Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine. 2011 Oct 19;29(45):8049-59.

• Haaheim LR, Katz JM. Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010. Influenza Other Respi Viruses. 2011 Jul;5(4):288-95.

• Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nostbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 2010 Dec 16;29(2):266-73.